Contact Lenses - Medical Devices Pipeline Assessment, 2016

Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 11
2.1 Contact Lenses Overview 11
3 Products under Development 12
3.1 Contact Lenses - Pipeline Products by Stage of Development 12
3.2 Contact Lenses - Pipeline Products by Segment 13
3.3 Contact Lenses - Pipeline Products by Territory 14
3.4 Contact Lenses - Pipeline Products by Regulatory Path 15
3.5 Contact Lenses - Pipeline Products by Estimated Approval Date 16
3.6 Contact Lenses - Ongoing Clinical Trials 17
4 Contact Lenses - Pipeline Products under Development by Companies 18
4.1 Contact Lenses Companies - Pipeline Products by Stage of Development 18
4.2 Contact Lenses - Pipeline Products by Stage of Development 20
5 Contact Lenses Companies and Product Overview 23
5.1 Aeon Astron Corporation Company Overview 23
5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Alcon, Inc. Company Overview 24
5.2.1 Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
5.3 Apeliotus Ophthalmics Company Overview 29
5.3.1 Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview 29
5.4 Auburn University Company Overview 31
5.4.1 Auburn University Pipeline Products & Ongoing Clinical Trials Overview 31
5.5 Axcelon Biopolymers Corp. Company Overview 33
5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 33
5.6 Bausch & Lomb Incorporated Company Overview 34
5.6.1 Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview 34
5.7 Body Organ Biomedical Corp. Company Overview 38
5.7.1 Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview 38
5.8 Children's Hospital Boston Company Overview 40
5.8.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 40
5.9 CooperVision, Inc. Company Overview 42
5.9.1 CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
5.10 EP Global Communications, Inc. Company Overview 43
5.10.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
5.11 Euclid Systems Corporation Company Overview 44
5.11.1 Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
5.12 Eyenovations Company Overview 45
5.12.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 45
5.13 EyeYon Medical Company Overview 46
5.13.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 46
5.14 Imperial College London Company Overview 49
5.14.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 49
5.15 Johnson & Johnson Vision Care, Inc. Company Overview 50
5.15.1 Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
5.16 Massachusetts Eye and Ear Infirmary Company Overview 54
5.16.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 54
5.17 Novartis AG Company Overview 56
5.17.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 56
5.18 Ocular Dynamics, LLC Company Overview 57
5.18.1 Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 57
5.19 Ocutec Limited Company Overview 58
5.19.1 Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview 58
5.20 Presbia Plc Company Overview 59
5.20.1 Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 59
5.21 Stanford University Company Overview 62
5.21.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 62
5.22 The Hong Kong University of Science and Technology Company Overview 63
5.22.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 63
5.23 The University of New South Wales Company Overview 64
5.23.1 The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 64
5.24 UltraVision CLPL Company Overview 65
5.24.1 UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 65
5.25 University of California, San Diego Company Overview 66
5.25.1 University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview 66
5.26 University of Florida Company Overview 68
5.26.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 68
5.27 University of Valencia Company Overview 69
5.27.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 69
5.28 University of Washington Company Overview 71
5.28.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 71
5.29 University of Western Ontario Company Overview 74
5.29.1 University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview 74
5.30 Valeant Pharmaceuticals International, Inc. Company Overview 75
5.30.1 Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
5.31 Visioneering Technologies, Inc. Company Overview 95
5.31.1 Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
5.32 VISTAKON Pharmaceuticals, LLC Company Overview 101
5.32.1 VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview 101
5.33 Yolia Health Company Overview 102
5.33.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 102
6 Contact Lenses- Recent Developments 103
6.1 Mar 03, 2016: The Cooper Companies Announces First Quarter 2016 Results 103
6.2 Mar 01, 2016: First Patients in Presbia Microlens FDA Study Complete 12-Month Postoperative Visits 104
6.3 Feb 19, 2016: Strong growth in revenue and earnings Essilor focused on its 2018 objectives 104
6.4 Feb 12, 2016: Carl Zeiss Meditec Grows, Boosted by Currency Tailwinds / Strongest Growth Once Again in Surgical Ophthalmology 105
6.5 Feb 05, 2016: Briefing Summary of the Analyst/Investor Meeting for the 3rd Quarter Financial Results for the Fiscal Year Ending March 31, 2016 Tokyo, January 29, 2016 106
6.6 Jan 29, 2016: Hoya Reports Third Quarter Results; Record Nine Months Results 109
6.7 Jan 27, 2016: Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations 110
6.8 Jan 15, 2016: HOYA Presents Hoya EyeGenius 119
6.9 Dec 16, 2015: AEA Investors to Acquire Majority Stake in 1-800 Contacts from Thomas H. Lee Partners 120
6.10 Dec 16, 2015: Carl Zeiss Meditec increases revenue to € 1,040 million / Market shares expanded in a number of markets 120
6.11 Dec 03, 2015: The Cooper Companies Announces Fourth Quarter and Full Year 2015 Results 121
6.12 Nov 10, 2015: Bausch + Lomb Announces 2016 Launch of Bausch + Lomb ULTRA Contact Lenses for Presbyopia 122
6.13 Nov 09, 2015: Unicon Optical to Acquire Taiwan-Based Contact Lenses Company 123
6.14 Nov 06, 2015: Shanghai Conant Optics Plans to Raise up to USD188.6 Million in Private Placement of Shares 123
6.15 Oct 27, 2015: Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance 123
6.16 Oct 26, 2015: Valeant Pharma Receives FTC Voluntary Request Letter Related To Paragon Holdings Acquisition 130
6.17 Oct 12, 2015: EPGL to Grant CooperVision Exclusive Licenses in Exchange for Royalties and Compensation Agreement by November 6, 2015 131
6.18 Oct 08, 2015: Robins Kaplan LLP Named Co-Lead Counsel in Disposable Contact Lens Antitrust Litigation 131
6.19 Oct 05, 2015: Presbia Introduces Time-Saving Disposable Microlens Inserter 132
6.20 Sep 17, 2015: Presbia Flexivue Microlens Implanted in More Than 1,000 Patients Worldwide 132
6.21 Sep 17, 2015: QSpex Technologies Enters into Agreement with Shanghai Conant Optical 132
6.22 Sep 14, 2015: HOYA Vision Care Establishes Subsidiary in Turkey 133
6.23 Sep 10, 2015: Presbia Completes Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens 133
6.24 Sep 10, 2015: Johnson & Johnson Vison Care Launches New Lens With A Tear-Infused Design 133
6.25 Sep 03, 2015: Presbia to Complete Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens 134
6.26 Sep 03, 2015: The Cooper Companies Announces Third Quarter 2015 Results 135
6.27 Aug 24, 2015: Results of Patient Outcomes Outside of the U.S. Demonstrate Safety and Effectiveness of Presbia Flexivue Mircolens 136
6.28 Aug 10, 2015: Presbia Surpasses Treatment of 300 Subjects as Part of the US FDA Pivotal Study Enrollment 136
6.29 Aug 05, 2015: Essilor International Raises USD328.4 Million in Public Offering of Notes Due 2017 137
6.30 Aug 03, 2015: Xavier Galliot, Chief Sustainability Officer of the Essilor Group 137
6.31 Jul 30, 2015: Essilor of America to Acquire Vision Source from Brazos Private Equity 137
6.32 Jul 30, 2015: Essilor Announces Strong results ; A winning strategy 137
6.33 Jul 29, 2015: Hoya Announces First Quarter Results Ended June 30, 2015 138
6.34 Jul 29, 2015: Hoya Reports First Quarter Financial Results 140
6.35 Jul 28, 2015: Valeant Pharmaceuticals Presented with Economic Development Support from Rochester Gas & Electric for the Bausch + Lomb ULTRA Contact Lens Manufacturing Line Expansion in Rochester, NY 141
6.36 Jul 21, 2015: Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches 141
6.37 Jul 13, 2015: Valeant Pharma to Acquire Unilens Vision 149
6.38 Jul 09, 2015: Presbia Reaches the Halfway Mark in Second Stage Enrollment in the US FDA Pivotal Study 149
6.39 Jun 23, 2015: Bausch + Lomb’s Biotrue ONEday for Presbyopia Contact Lenses Now Available in Expanded High Add Powers 149
6.40 Jun 22, 2015: Visioneering Technologies Taps MidSouth Premier Ophthalmics as Exclusive Distributor for NaturalVue Lenses 150
6.41 Jun 04, 2015: The Cooper Companies Announces Second Quarter 2015 Results 150
6.42 Jun 01, 2015: NVISION Eye Centers Performs First KAMRA Inlay in California 151
6.43 May 15, 2015: Ultravision Expands Licensing Agreement with Art Optical 152
6.44 May 14, 2015: Unilens Vision Reports Third Quarter Operating Results 152
6.45 May 12, 2015: Hoya Reports Fourth Quarter Results; Achieves Record Annual Sales and Profit 154
6.46 May 04, 2015: NVISION Eye Centers Becomes One of the First in the U.S. to Offer Breakthrough KAMRA Inlay for Near Vision Loss Associated With Aging 155
6.47 May 03, 2015: Bausch + Lomb Presents New Scientific and Clinical Research During the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, CO 155
6.48 Apr 23, 2015: Novartis delivered sales growth, significant margin expansion and strong innovation in Q1; now with a more focused portfolio 156
6.49 Apr 21, 2015: Presbia Announces the Start of Commercialization of the Presbia Flexivue Micolens in Australia 163
6.50 Apr 21, 2015: Revenue up very sharply by 25.4% Annual targets confirmed 163
6.51 Apr 18, 2015: Durrie Vision First in Region to Provide Corneal Implant Designed to Treat Presbyopia 165
6.52 Apr 18, 2015: ZEISS Showcases Integrated Solutions that Deliver Faster Practice and Surgical Workflow and Address Critical Diagnostic Challenges 165
6.53 Apr 17, 2015: FDA approves first-of-its-kind corneal implant to improve near vision in certain patients 167
6.54 Apr 16, 2015: Visioneering Technologies Introduces NaturalVue 1 Day Multifocal Contact Lens Works with the Brain to Optimize Vision 168
7 Appendix 169
7.1 Methodology 169
7.2 About GlobalData 171
7.3 Contact Us 172
7.4 Disclaimer 172
List Of Tables
1.1 List of Tables
Table 1: Contact Lenses - Pipeline Products by Stage of Development 12
Table 2: Contact Lenses - Pipeline Products by Segment 13
Table 3: Contact Lenses - Pipeline Products by Territory 14
Table 4: Contact Lenses - Pipeline Products by Regulatory Path 15
Table 5: Contact Lenses - Pipeline Products by Estimated Approval Date 16
Table 6: Contact Lenses - Ongoing Clinical Trials 17
Table 7: Contact Lenses Companies - Pipeline Products by Stage of Development 18
Table 8: Contact Lenses - Pipeline Products by Stage of Development 20
Table 9: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
Table 10: Body Organ Contact Lens - Product Status 23
Table 11: Body Organ Contact Lens - Product Description 23
Table 12: Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
Table 13: Dailies Total 1 Colors SiHy Lens - Product Status 24
Table 14: Dailies Total 1 Colors SiHy Lens - Product Description 24
Table 15: Dailies Total 1 Multifocal SiHy Lens - Product Status 25
Table 16: Dailies Total 1 Multifocal SiHy Lens - Product Description 25
Table 17: Dailies Total 1 Toric SiHy Lens - Product Status 26
Table 18: Dailies Total 1 Toric SiHy Lens - Product Description 26
Table 19: Smart Lens - Diabetes - Product Status 27
Table 20: Smart Lens - Diabetes - Product Description 27
Table 21: Weekly WG SiHy Lens - Product Status 28
Table 22: Weekly WG SiHy Lens - Product Description 28
Table 23: Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview 29
Table 24: Comfort Lens - Product Status 29
Table 25: Comfort Lens - Product Description 29
Table 26: Contact Lens - Glaucoma - Product Status 30
Table 27: Contact Lens - Glaucoma - Product Description 30
Table 28: Auburn University Pipeline Products & Ongoing Clinical Trials Overview 31
Table 29: Smart Contact Lenses - Product Status 32
Table 30: Smart Contact Lenses - Product Description 32
Table 31: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 33
Table 32: MC - PHEMA Based Contact Lens - Product Status 33
Table 33: MC - PHEMA Based Contact Lens - Product Description 33
Table 34: Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview 34
Table 35: Ultra Multi Focal Lens - Product Status 35
Table 36: Ultra Multi Focal Lens - Product Description 35
Table 37: Ultra Plus Powers Lens - Product Status 36
Table 38: Ultra Plus Powers Lens - Product Description 36
Table 39: Ultra Toric Lens - Product Status 37
Table 40: Ultra Toric Lens - Product Description 37
Table 41: Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview 38
Table 42: Biolens - Product Status 39
Table 43: Biolens - Product Description 39
Table 44: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 40
Table 45: Contact Lens Drug Delivery Device - Product Status 41
Table 46: Contact Lens Drug Delivery Device - Product Description 41
Table 47: CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
Table 48: SiH Multifocal - Product Status 42
Table 49: SiH Multifocal - Product Description 42
Table 50: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
Table 51: EP Global Contact Lens - Product Status 43
Table 52: EP Global Contact Lens - Product Description 43
Table 53: Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
Table 54: Drug-Eluting Contact Lenses - Product Status 44
Table 55: Drug-Eluting Contact Lenses - Product Description 44
Table 56: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 45
Table 57: Drug Dispensing Contact Lens - Product Status 45
Table 58: Drug Dispensing Contact Lens - Product Description 45
Table 59: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 46
Table 60: Hyper-CL - Product Status 46
Table 61: Hyper-CL - Product Description 46
Table 62: EyeYon Medical - Ongoing Clinical Trials Overview 47
Table 63: Hyper-CL - Prospective, Randomized Crossover Study of Using the Hyper-CL Lens (Hyper Osmotic Contact Lens) in Subjects Suffering from Corneal Edema 48
Table 64: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 49
Table 65: Contact Lens - Product Status 49
Table 66: Contact Lens - Product Description 49
Table 67: Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
Table 68: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 51
Table 69: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 51
Table 70: Anti-allergic Contact Lens - Product Status 52
Table 71: Anti-allergic Contact Lens - Product Description 52
Table 72: Next Generation 1-DAY ACUVUE DEFINE Contact Lens - Product Status 53
Table 73: Next Generation 1-DAY ACUVUE DEFINE Contact Lens - Product Description 53
Table 74: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 54
Table 75: Therapeutic Contact Lens - Product Status 55
Table 76: Therapeutic Contact Lens - Product Description 55
Table 77: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 56
Table 78: CLM041 - Product Status 56
Table 79: CLM041 - Product Description 56
Table 80: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 57
Table 81: Contact Lens - Dry Eye Disease - Product Status 57
Table 82: Contact Lens - Dry Eye Disease - Product Description 57
Table 83: Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview 58
Table 84: Third PEG Hydrogel Contact Lens - Product Status 58
Table 85: Third PEG Hydrogel Contact Lens - Product Description 58
Table 86: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 59
Table 87: Flexivue Microlens - Product Status 59
Table 88: Flexivue Microlens - Product Description 59
Table 89: Presbia Plc - Ongoing Clinical Trials Overview 60
Table 90: Flexivue Microlens - A Phase II trial of Presbia Flexivue Microlens for The Treatment of Presbyopia 61
Table 91: Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes 61
Table 92: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 62
Table 93: Polymer Network Hydrogel Contact Lens - Product Status 62
Table 94: Polymer Network Hydrogel Contact Lens - Product Description 62
Table 95: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 63
Table 96: Resonance Circuit Sensor Contact Lens - Product Status 63
Table 97: Resonance Circuit Sensor Contact Lens - Product Description 63
Table 98: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 64
Table 99: Stem Cell Contact Lens - Product Status 64
Table 100: Stem Cell Contact Lens - Product Description 64
Table 101: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 65
Table 102: Contact Lenses - Product Status 65
Table 103: Contact Lenses - Product Description 65
Table 104: University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview 66
Table 105: Aerated Contact Lens - Product Status 66
Table 106: Aerated Contact Lens - Product Description 66
Table 107: Telescopic Contact Lens - Product Status 67
Table 108: Telescopic Contact Lens - Product Description 67
Table 109: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 68
Table 110: Vitamin E - Packed Lenses - Product Status 68
Table 111: Vitamin E - Packed Lenses - Product Description 68
Table 112: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 69
Table 113: Multifocal Contact Lens - Myopia - Product Status 69
Table 114: Multifocal Contact Lens - Myopia - Product Description 69
Table 115: Multifocal Contact Lens - Presbyopia - Product Status 70
Table 116: Multifocal Contact Lens - Presbyopia - Product Description 70
Table 117: University of Washington Pipeline Products & Ongoing Clinical Trials Overview 71
Table 118: Bionic Contact Lens - Product Status 72
Table 119: Bionic Contact Lens - Product Description 72
Table 120: Solar Powered Augmented Lenses - Product Status 73
Table 121: Solar Powered Augmented Lenses - Product Description 73
Table 122: University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview 74
Table 123: Nanocomposite Hydrogel Lenses - Product Status 74
Table 124: Nanocomposite Hydrogel Lenses - Product Description 74
Table 125: Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
Table 126: BLC - 001: SVS - Product Status 76
Table 127: BLC - 001: SVS - Product Description 76
Table 128: BLC - 002: SVS - Product Status 77
Table 129: BLC - 002: SVS - Product Description 77
Table 130: BLC - 003: SVS/MF/fA - Product Status 78
Table 131: BLC - 003: SVS/MF/fA - Product Description 78
Table 132: BLC - 004: Toric - Product Status 79
Table 133: BLC - 004: Toric - Product Description 79
Table 134: BLC - 005: SVS/MF - Product Status 80
Table 135: BLC - 005: SVS/MF - Product Description 80
Table 136: BLC - 006: SVS - Product Status 81
Table 137: BLC - 006: SVS - Product Description 81
Table 138: BLC - 007: MF - Product Status 82
Table 139: BLC - 007: MF - Product Description 82
Table 140: BLC - 008: Astigmatism - Product Status 83
Table 141: BLC - 008: Astigmatism - Product Description 83
Table 142: BLC - 009: Astigmatism - Product Status 84
Table 143: BLC - 009: Astigmatism - Product Description 84
Table 144: XUV - 003: Aphakia - Product Status 85
Table 145: XUV - 003: Aphakia - Product Description 85
Table 146: XUV - 004: SVS - Product Status 86
Table 147: XUV - 004: SVS - Product Description 86
Table 148: XUV - 007: MF - Product Status 87
Table 149: XUV - 007: MF - Product Description 87
Table 150: XUV - 009: SVS - Product Status 88
Table 151: XUV - 009: SVS - Product Description 88
Table 152: XUV - 010: Astigmatism - Product Status 89
Table 153: XUV - 010: Astigmatism - Product Description 89
Table 154: XUV - 011: MF - Product Status 90
Table 155: XUV - 011: MF - Product Description 90
Table 156: XUV - 012: SVS - Product Status 91
Table 157: XUV - 012: SVS - Product Description 91
Table 158: XUV - 013: SVS - Product Status 92
Table 159: XUV - 013: SVS - Product Description 92
Table 160: XUV - 014: Presbyopia - Product Status 93
Table 161: XUV - 014: Presbyopia - Product Description 93
Table 162: XUV - 015: MF - Product Status 94
Table 163: XUV - 015: MF - Product Description 94
Table 164: Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
Table 165: Contact Lens - Product Status 96
Table 166: Contact Lens - Product Description 96
Table 167: NaturalVue Sphere 1 Day Contact Lenses - Product Status 97
Table 168: NaturalVue Sphere 1 Day Contact Lenses - Product Description 97
Table 169: NaturalVue Toric 1 Day Contact Lenses - Product Status 98
Table 170: NaturalVue Toric 1 Day Contact Lenses - Product Description 98
Table 171: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Status 99
Table 172: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Description 99
Table 173: VTI MPC Lens - Product Status 100
Table 174: VTI MPC Lens - Product Description 100
Table 175: VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview 101
Table 176: K-Lens - Product Status 101
Table 177: K-Lens - Product Description 101
Table 178: Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 102
Table 179: TVT Device - Product Status 102
Table 180: TVT Device - Product Description 102
Table 181: Glossary 170
List Of Figures
1.2 List of Figures
Figure 1: Contact Lenses - Pipeline Products by Stage of Development 12
Figure 2: Contact Lenses - Pipeline Products by Segment 13
Figure 3: Contact Lenses - Pipeline Products by Territory 14
Figure 4: Contact Lenses - Pipeline Products by Regulatory Path 15
Figure 5: Contact Lenses - Pipeline Products by Estimated Approval Date 16
Figure 6: Contact Lenses - Ongoing Clinical Trials 17

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.